Thread by @MPishvaian

#ASCO21

🙏Thank you all for the positive feedback on the PDAC Abstracts

➡️Here now is my 2nd list
✅My Top NON-Pancreatic abstracts to watch for...in no particular order.....

📝Again, I tagged who I could (whose hashtag I could find)

#ASCO21

There were several potential practice changing studies including the one Late Breaking Abstract teaser:

➡️I Chau, et al (LBA 4001)
✅Nivo + ipi or Nivo + chemo vs. chemo alone as 1st-line Tx for esophageal SCC: CheckMate 648

🧐Will dual IO be the winner❓

#ASCO21

➡️R-H Xu, et al (abstr 4000)
✅Ph 3 trial of camrelizumab plus chemo vs. chemo in patients with advanced esophageal SCC
👉Paclitaxel + cis +/- camrelizumab
👉596 patients randomized

🎉Camrelizumab plus chemotherapy⬆️mOS (15.3 vs. 12.0 mos) and ⬆️ORR (72.1% vs. 62.1%)

#ASCO21

➡️DP Modest, et al (abstr 3503)
✅Maintenance 5FU + panitumumab vs. 5FU alone for mCRC - the PANAMA trial
👉🎉248 pts randomized
5FU + pmab ⬆️PFS vs. 5FU alone (8.8 vs 5.7 mos)

🙏Thank you - 🧐I actually was faced with the❓of maintenance 5FU/Pmab just a few weeks ago

#ASCO21

➡️A Sartore-Bianchi, et al (abstr 3506)
✅Anti-EGFR rechallenge Ph2 CHRONOS trial
👉Mut RAS clones⬇️with anti-EGFR withdrawal
👉52 pts screened
👉36 (69%) neg for RAS/BRAF/EGFR muts

🎉Of 27 treated with pMab - 8 PRs (ORR = 30%)
🎉DCR (> 4 mos) in 16/27 (59%)

#ASCO21

➡️CH Yoo, et al (abstr 4006)
✅5FU/nal-IRI vs 5FU in met biliary tract cancer after GemCis: NIFTY
👉174 pts analyzed

🎉5FU/nal-IRI⬆️PFS vs 5FU (3.9 vs. 1.6 mos)
🎉5FU/nal-IRI⬆️OS vs 5FU (8.6 vs. 5.5 mos)
🎉5FU/nal-IRI⬆️ORR vs 5FU (BICR) (15% vs. 6%)

#ASCO21

Several key targeted Tx trials:

➡️@YJanjigianMD et al (abstr 4013)
✅Trastuzumab & chemo (SOC) +/- pembro for HER2+ metG/GEJ cancer: KEYNOTE-811
👉First 264 pts randomized (0.8% had MSI-H tumors)

🎉Pembro⬆️ORR (74.4% vs. 51.9%)

#ASCO21

➡️@DocCatenacci et al (abstr 4010)
✅FIGHT:1L FOLFOX +/- bemarituzumab in FGFR2b+ advanced G/GEJ cancer
👉Bema is a mAb to FGFR2b
👉155 pts randomized (96 w/FGFR2b IHC 2/3+ in ≥10% of cells)

🎉Bema⬆️OS (19.2mo vs 13.5mo) ITT
🎉Bema⬆️OS (25.4mo vs 11.1mo) in ≥10%+ pts

#ASCO21

➡️T Yoshino, et al (abstr 3505)
✅Final results of T-DXd (DS-8201) in pts w/HER2-expressing mCRC
👉86 pts treated

🎉ORR = 45.3%
🎉DCR = 83.0%
🎉mPFS = 6.9 mo
🎉mOS = 15.5 mo

#ASCO21

There were MULTIPLE VEGF inh + PD-1 inh combination trials:
➡️Y Guo, et al (abstr 2514): Fruquintinib + Sintilimab
➡️CA Gomez-Roca, et al (abstr 3564): LEAP-005, Lenva + Pembro
➡️M Fakih, et al (abstr 3560): Rego + nivo

✅In MSS mCRC the ORR was consistently ~20%

#ASCO21

Also VEGF inh + PD-1 inh combos in BTC & gastric Ca:
➡️Z Jian (4099): LEAP-005, Lenva+toripa 1st line BTC
✅ORR=32%

➡️L Villanueva (4080): Lenva+Pembro BTC
✅ORR=10%

➡️S Cousin (4096): Rego+Avelu BTC
✅ORR=14%

➡️HCC Chung (4030): Lenva+Pembro Gastric Ca
✅ORR=10%

#ASCO21

➡️Finally K Ludford, @drsmags @skopetz @michael_overman and others
✅An exciting trial of neoadj pembro in MMRdef localized Ca (72% resectable)
👉24 CRC & 8 non-CRC

🎉ORR = 77%, 30% CR, 47% PR, Only 1 PD
🎉pCR in 3/6 who had surgery

#ASCO21

Oh no! I definitely meant to mention this trial too:
➡️J Strauss @gulleyj1 & others (abstr 2501)
✅Ph 2 of PDS0101, M9241, and bintrafusp alfa in pts with HPV 16 + Ca

🎉10/14 enrolled pts responded (71%) inc. 1CR and 2PRs in ASCC patients